Immuron Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
6,141.80
3,116.10
2,290.60
3,994.90
4,727.40
Total Accounts Receivable
517.80
216.20
4,387.80
1,768.20
1,683.30
Inventories
566.00
1,146.30
2,056.10
2,336.10
497.90
Other Current Assets
386.60
50.60
74.90
168.40
141.80
Total Current Assets
7,612.20
4,529.10
8,809.40
8,267.70
7,050.40
Net Property, Plant & Equipment
20.10
19.50
18.10
18.80
20.40
Total Investments and Advances
0.00
0.00
-
-
-
Other Assets
-
-
-
-
2,171.90
Total Assets
7,632.20
4,548.60
8,827.50
8,286.50
9,242.70
ST Debt & Current Portion LT Debt
-
-
1,900.50
365.90
-
Accounts Payable
652.60
918.50
1,517.30
699.50
689.30
Other Current Liabilities
192.70
289.30
469.20
646.20
114.00
Total Current Liabilities
845.30
1,207.80
3,886.90
1,711.60
803.30
Total Liabilities
845.30
1,207.80
3,886.90
1,711.60
803.30
Common Equity (Total)
6,786.90
3,340.80
4,940.60
6,574.90
8,439.40
Total Shareholders' Equity
6,786.90
3,340.80
4,940.60
6,574.90
8,439.40
Total Equity
6,786.90
3,340.80
4,940.60
6,574.90
8,439.40
Liabilities & Shareholders' Equity
7,632.20
4,548.60
8,827.50
8,286.50
9,242.70

About Immuron

View Profile
Address
62 Lygon Street
Carlton Victoria (VIC) 3053
Australia
Employees -
Website http://www.immuron.com
Updated 07/08/2019
Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the research and development projects performed in Australia and Israel.